[
    {
        "indication": "Non-Small Cell Lung Cancer",
        "therapy_area": "Oncology",
        "patient_burden_score": 9.1,
        "active_trials": [
            {
                "nct_id": "NCT01234567",
                "phase": "Phase III",
                "drug_name": "Pembrolizumab",
                "sponsor": "Merck Sharp & Dohme"
            },
            {
                "nct_id": "NCT07654321",
                "phase": "Phase II",
                "drug_name": "Novel IO Agent",
                "sponsor": "Roche"
            },
            {
                "nct_id": "NCT05891234",
                "phase": "Phase III",
                "drug_name": "Pembrolizumab + Lenvatinib",
                "sponsor": "Merck/Eisai"
            }
        ],
        "competition_density": "Medium",
        "unmet_need": "High"
    },
    {
        "indication": "Type 2 Diabetes",
        "therapy_area": "Diabetes",
        "patient_burden_score": 8.5,
        "active_trials": [
            {
                "nct_id": "NCT09876543",
                "phase": "Phase IV",
                "drug_name": "Sitagliptin",
                "sponsor": "Merck"
            },
            {
                "nct_id": "NCT04789012",
                "phase": "Phase III",
                "drug_name": "Semaglutide Oral",
                "sponsor": "Novo Nordisk"
            },
            {
                "nct_id": "NCT05123890",
                "phase": "Phase III",
                "drug_name": "Tirzepatide",
                "sponsor": "Eli Lilly"
            }
        ],
        "competition_density": "High",
        "unmet_need": "Medium"
    },
    {
        "indication": "Idiopathic Pulmonary Fibrosis",
        "therapy_area": "Respiratory",
        "patient_burden_score": 8.5,
        "active_trials": [
            {
                "nct_id": "NCT04123456",
                "phase": "Phase III",
                "drug_name": "Pirfenidone",
                "sponsor": "Roche"
            },
            {
                "nct_id": "NCT05234890",
                "phase": "Phase II",
                "drug_name": "Pamrevlumab",
                "sponsor": "FibroGen"
            }
        ],
        "competition_density": "Low",
        "unmet_need": "High"
    },
    {
        "indication": "COPD",
        "therapy_area": "Respiratory",
        "patient_burden_score": 9.2,
        "active_trials": [
            {
                "nct_id": "NCT04234567",
                "phase": "Phase II",
                "drug_name": "Roflumilast Extended Release",
                "sponsor": "AstraZeneca"
            },
            {
                "nct_id": "NCT04234568",
                "phase": "Phase III",
                "drug_name": "Ensifentrine",
                "sponsor": "Verona Pharma"
            },
            {
                "nct_id": "NCT05345678",
                "phase": "Phase III",
                "drug_name": "Tezepelumab",
                "sponsor": "AstraZeneca"
            }
        ],
        "competition_density": "Low",
        "unmet_need": "Very High"
    },
    {
        "indication": "Severe Asthma",
        "therapy_area": "Respiratory",
        "patient_burden_score": 7.8,
        "active_trials": [
            {
                "nct_id": "NCT04345678",
                "phase": "Phase III",
                "drug_name": "Tezepelumab",
                "sponsor": "Amgen/AstraZeneca"
            },
            {
                "nct_id": "NCT05456789",
                "phase": "Phase III",
                "drug_name": "Dupilumab",
                "sponsor": "Sanofi/Regeneron"
            }
        ],
        "competition_density": "Low",
        "unmet_need": "High"
    },
    {
        "indication": "Asthma",
        "therapy_area": "Respiratory",
        "patient_burden_score": 6.5,
        "active_trials": [
            {
                "nct_id": "NCT04456789",
                "phase": "Phase IV",
                "drug_name": "Fluticasone/Salmeterol",
                "sponsor": "GSK"
            },
            {
                "nct_id": "NCT04456790",
                "phase": "Phase III",
                "drug_name": "Budesonide/Formoterol",
                "sponsor": "AstraZeneca"
            },
            {
                "nct_id": "NCT04456791",
                "phase": "Phase II",
                "drug_name": "Novel ICS",
                "sponsor": "Cipla"
            },
            {
                "nct_id": "NCT04456792",
                "phase": "Phase III",
                "drug_name": "Ciclesonide",
                "sponsor": "Covis Pharma"
            }
        ],
        "competition_density": "High",
        "unmet_need": "Medium"
    },
    {
        "indication": "Pulmonary Arterial Hypertension",
        "therapy_area": "Respiratory",
        "patient_burden_score": 8.9,
        "active_trials": [
            {
                "nct_id": "NCT04567890",
                "phase": "Phase II",
                "drug_name": "Sotatercept",
                "sponsor": "Acceleron/Merck"
            }
        ],
        "competition_density": "Low",
        "unmet_need": "Very High"
    },
    {
        "indication": "Melanoma",
        "therapy_area": "Oncology",
        "patient_burden_score": 7.2,
        "active_trials": [
            {
                "nct_id": "NCT05123456",
                "phase": "Phase II",
                "drug_name": "Pembrolizumab + Novel Agent",
                "sponsor": "Merck"
            }
        ],
        "competition_density": "Medium",
        "unmet_need": "Medium"
    },
    {
        "indication": "Triple Negative Breast Cancer",
        "therapy_area": "Oncology",
        "patient_burden_score": 8.1,
        "active_trials": [
            {
                "nct_id": "NCT05234567",
                "phase": "Phase III",
                "drug_name": "Pembrolizumab + Chemotherapy",
                "sponsor": "Merck Sharp & Dohme"
            },
            {
                "nct_id": "NCT05345890",
                "phase": "Phase II",
                "drug_name": "Sacituzumab Govitecan",
                "sponsor": "Gilead"
            }
        ],
        "competition_density": "Low",
        "unmet_need": "High"
    },
    {
        "indication": "Rheumatoid Arthritis",
        "therapy_area": "Autoimmune",
        "patient_burden_score": 7.5,
        "active_trials": [
            {
                "nct_id": "NCT05456123",
                "phase": "Phase III",
                "drug_name": "Upadacitinib",
                "sponsor": "AbbVie"
            },
            {
                "nct_id": "NCT05567234",
                "phase": "Phase III",
                "drug_name": "Adalimumab Biosimilar",
                "sponsor": "Biocon/Viatris"
            },
            {
                "nct_id": "NCT05678345",
                "phase": "Phase II",
                "drug_name": "Novel JAK Inhibitor",
                "sponsor": "Pfizer"
            }
        ],
        "competition_density": "High",
        "unmet_need": "Medium"
    },
    {
        "indication": "Major Depressive Disorder",
        "therapy_area": "CNS",
        "patient_burden_score": 8.8,
        "active_trials": [
            {
                "nct_id": "NCT05789456",
                "phase": "Phase III",
                "drug_name": "Esketamine",
                "sponsor": "Johnson & Johnson"
            },
            {
                "nct_id": "NCT05890567",
                "phase": "Phase II",
                "drug_name": "Psilocybin",
                "sponsor": "COMPASS Pathways"
            },
            {
                "nct_id": "NCT05901678",
                "phase": "Phase III",
                "drug_name": "Zuranolone",
                "sponsor": "Sage/Biogen"
            }
        ],
        "competition_density": "Medium",
        "unmet_need": "High"
    },
    {
        "indication": "Generalized Anxiety Disorder",
        "therapy_area": "CNS",
        "patient_burden_score": 7.9,
        "active_trials": [
            {
                "nct_id": "NCT06012789",
                "phase": "Phase III",
                "drug_name": "Escitalopram",
                "sponsor": "Generic"
            },
            {
                "nct_id": "NCT06123890",
                "phase": "Phase II",
                "drug_name": "Novel GABA Modulator",
                "sponsor": "Pfizer"
            }
        ],
        "competition_density": "High",
        "unmet_need": "Medium"
    },
    {
        "indication": "Obesity",
        "therapy_area": "Metabolic",
        "patient_burden_score": 8.7,
        "active_trials": [
            {
                "nct_id": "NCT06234901",
                "phase": "Phase III",
                "drug_name": "Retatrutide",
                "sponsor": "Eli Lilly"
            },
            {
                "nct_id": "NCT06345012",
                "phase": "Phase III",
                "drug_name": "Orforglipron",
                "sponsor": "Eli Lilly"
            },
            {
                "nct_id": "NCT06456123",
                "phase": "Phase III",
                "drug_name": "Semaglutide 2.4mg",
                "sponsor": "Novo Nordisk"
            }
        ],
        "competition_density": "Low",
        "unmet_need": "Very High"
    },
    {
        "indication": "HER2+ Breast Cancer",
        "therapy_area": "Oncology",
        "patient_burden_score": 7.4,
        "active_trials": [
            {
                "nct_id": "NCT06567234",
                "phase": "Phase III",
                "drug_name": "Trastuzumab Deruxtecan",
                "sponsor": "Daiichi Sankyo/AstraZeneca"
            },
            {
                "nct_id": "NCT06678345",
                "phase": "Phase III",
                "drug_name": "Margetuximab",
                "sponsor": "MacroGenics"
            }
        ],
        "competition_density": "Medium",
        "unmet_need": "Medium"
    },
    {
        "indication": "Crohn's Disease",
        "therapy_area": "Autoimmune",
        "patient_burden_score": 8.3,
        "active_trials": [
            {
                "nct_id": "NCT06789456",
                "phase": "Phase III",
                "drug_name": "Risankizumab",
                "sponsor": "AbbVie"
            },
            {
                "nct_id": "NCT06890567",
                "phase": "Phase III",
                "drug_name": "Upadacitinib",
                "sponsor": "AbbVie"
            },
            {
                "nct_id": "NCT06901678",
                "phase": "Phase II",
                "drug_name": "Guselkumab",
                "sponsor": "Janssen"
            }
        ],
        "competition_density": "Medium",
        "unmet_need": "High"
    },
    {
        "indication": "GERD",
        "therapy_area": "Gastrointestinal",
        "patient_burden_score": 5.8,
        "active_trials": [
            {
                "nct_id": "NCT07012789",
                "phase": "Phase IV",
                "drug_name": "Pantoprazole",
                "sponsor": "Generic"
            },
            {
                "nct_id": "NCT07123890",
                "phase": "Phase III",
                "drug_name": "Vonoprazan",
                "sponsor": "Takeda"
            }
        ],
        "competition_density": "High",
        "unmet_need": "Low"
    },
    {
        "indication": "Community Acquired Pneumonia",
        "therapy_area": "Anti-infective",
        "patient_burden_score": 7.1,
        "active_trials": [
            {
                "nct_id": "NCT07234901",
                "phase": "Phase IV",
                "drug_name": "Azithromycin",
                "sponsor": "Generic"
            },
            {
                "nct_id": "NCT07345012",
                "phase": "Phase III",
                "drug_name": "Lefamulin",
                "sponsor": "Nabriva"
            }
        ],
        "competition_density": "High",
        "unmet_need": "Medium"
    },
    {
        "indication": "Multiple Myeloma",
        "therapy_area": "Oncology",
        "patient_burden_score": 8.6,
        "active_trials": [
            {
                "nct_id": "NCT07456123",
                "phase": "Phase III",
                "drug_name": "Carfilzomib",
                "sponsor": "Amgen"
            },
            {
                "nct_id": "NCT07567234",
                "phase": "Phase III",
                "drug_name": "Daratumumab",
                "sponsor": "Janssen"
            },
            {
                "nct_id": "NCT07678345",
                "phase": "Phase II",
                "drug_name": "Teclistamab",
                "sponsor": "Janssen"
            }
        ],
        "competition_density": "Medium",
        "unmet_need": "High"
    }
]